23ME610 is under clinical development by 23andMe Holding and currently in Phase II for Merkel Cell Carcinoma.
Existing drug shows promise for treating common liver disease
The University of Barcelona has led a study that suggests using the drug known as pemafibrate to treat liver disease associated with metabolic disorders, the